Life sciences consulting firms Litmys and PharmaACE have officially announced a strategic collaboration designed to deliver specialised decision-making and commercial forecasting solutions to the biotechnology and pharmaceutical sectors. This newly formed partnership specifically integrates real-world product adoption analytics with sophisticated commercial modelling. The core objective is to support companies in making informed choices regarding clinical development, financial investments, and overall commercialisation strategies.
Advancing Analytics In Life Sciences Consulting
By linking their distinct analytical tools, the companies intend to produce market projections rooted in actual customer behaviour rather than relying on standard assumptions. Historically, conventional industry forecasts have frequently depended on baseline metrics such as clinical profiles, total market scale, and expected market share. The joint initiative instead evaluates exactly how interactions between healthcare providers, payers, and patients directly drive uptake. Through this focused evaluation, the life sciences consulting specialists aim to help companies effectively identify commercial risks well before finalising any major clinical development decisions.
Re-evaluating Adoption Through Specialised Models
Litmys managing partner Harris Kaplan said: “Approval does not equal adoption, and a forecast is only as good as the assumptions behind it. Our work focuses on understanding what will actually drive physicians, payers, and patients to embrace a new product. Combining that perspective with PharmaACE’s sophisticated forecasting and analytics capabilities allows us to connect the drivers of adoption more directly to commercial expectations and help clients make better decisions while they still have time to influence the outcome.”
To achieve these results, Litmys applies its Realistic Assessment of Market Potential (RAMPx) methodology. This proprietary framework assesses product advantages, uptake barriers, and stakeholder willingness to alter current behaviours. Following this, PharmaACE implements targeted models, commercial analytics, and consulting expertise to effectively translate the resulting findings into precise market projections. Together, Litmys and PharmaACE plan to deliver complementary services spanning the entire product lifecycle, starting from early clinical development through to product launch, while establishing an assessment framework to evaluate assets and allocate resources across international portfolios.
Corporate Presence And Expertise Across Global Markets
Litmys is headquartered in Santa Fe, New Mexico, within the United States. The firm also maintains an additional site located in Minneapolis, Minnesota, which focuses exclusively on commercial readiness analytics and development risk assessment for medicines and medical devices.
Established in 2013, PharmaACE is based in Princeton, New Jersey, and currently maintains active offices in Canada, Germany, India, and Portugal. The consultancy delivers comprehensive analytics, commercial forecasting, and advisory services across several major therapy areas. These specific areas include cardiometabolic conditions, central nervous system disorders, immunology, oncology, and rare diseases, thereby strengthening their mutual capacity to assess real-world product adoption globally.
